Abstract Body

The presence and quantification of HIV in the brain is important for eradication as neuropathological studies suggest that latent brain HIV varies considerably amongst individuals. HAND, both past and stable in virally suppressed (VS) patients is associated with brain latency and may serve as a latency biomarker discovery approach. We hypothesized that putative brain latency biomarkers would differ in VS past/stable HAND vs. non-HAND.

24 HIV+ men (age M=52.67±12.72; HIV infection duration: M=17.75±12.69 years) who were VS (in plasma <100cpml and CSF <100cpml) on cART underwent lumbar puncture and neuropsychological testing. Patients with past HAND from which they had recovered and patients with stable HAND (past/stable HAND group) were compared to patients with no known past or current CNS involvement (non-HAND group) for putative markers of HIV brain latency: CSF HIV RNA by single copy assay (SCA), HIV tat, BCL11b, neurofilament-light chain (NFL), neopterin, CCL2, and CSF:serum albumin ratio (Q-Alb). CSF markers were classified as normal/abnormal using normal references and a combined CSF latency biomarker risk score was created by summing the number of abnormal values. HAND status was defined using Global Deficit Score (GDS≥0.5). Past HAND was determined from medical record review.

Low level HIV persistence (CSF HIV RNA SCA >1-12.4 cpml) was detected in CSF in both groups (17% of past/stable HAND and 24% of non-HAND; p=73) and HIV tat was also detected in both groups (17% of past/stable HAND and 6% for non-HAND; p=.42) (SCA was <1cpml in each case). BCL11b levels were similar across the board. However, the past/stable HAND group showed higher NFL levels (p=.05) than the non-HAND group. Neopterin was abnormal in many patients (57% of past/stable HAND and 31% of non-HAND; p=.24). CCL2 and Q-Alb levels were largely normal and similar in both groups. Consequently, the combined CSF latency biomarker risk score did not differ across groups (p=.58).

Past/stable HAND is not a useful model for identifying brain latency biomarkers using the latter markers. Past/stable HAND remains an active virological immunological and degenerative process. The concept of a “legacy effect” from past HAND is not supported.